Earth Science Tech Launches Cash-Flow-Positive Telehealth Platform, Integrating with Pharmacies
summarizeSummary
Earth Science Tech, Inc. announced the launch of MyOnlineConsultation.com, a new telehealth and pharmacy platform that is already cash-flow-positive and expected to significantly boost revenue through vertical integration.
check_boxKey Events
-
Telehealth Platform Launch
The company officially launched MyOnlineConsultation.com through MOCTeledoc, LLC, establishing a fully vertically integrated telehealth and pharmacy ecosystem.
-
Immediate Cash-Flow Positive
MOCTeledoc achieved cash-flow-positive status during its beta phase, validating its business model and indicating immediate accretive potential.
-
Significant Revenue Growth Strategy
Management projects MOCTeledoc will become a significant revenue stream, complementing the company's existing compounding and direct-to-consumer divisions which generated $25.9 million in revenue for the nine months ended December 31, 2025.
-
Enhanced Vertical Integration
The launch finalizes ETST's healthcare ecosystem by synchronizing MOCTeledoc's prescriber network directly with the company's compounding pharmacies (RxCompound and Mister Meds) and other pharmacies.
auto_awesomeAnalysis
Earth Science Tech, Inc. has launched MyOnlineConsultation.com, a new telehealth and pharmacy ecosystem that is already cash-flow-positive from its beta phase. This strategic move completes the company's vertical integration, linking its prescriber network directly with its compounding pharmacies and other facilities. Management anticipates this new division will become a significant revenue stream, building on the company's existing $25.9 million in revenue for the nine months ended December 31, 2025. The immediate cash-flow-positive status and the creation of a new revenue funnel for its in-house pharmacies are positive indicators for future growth and profitability.
At the time of this filing, ETST was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.1M. The 52-week trading range was $0.00 to $0.24. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.